These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27716258)

  • 1. Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial.
    Menozzi A; Dall'Aglio M; Quintavalla F; Dallavalle L; Meucci V; Bertini S
    BMC Vet Res; 2016 Oct; 12(1):217. PubMed ID: 27716258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial.
    Jergens AE; Crandell J; Morrison JA; Deitz K; Pressel M; Ackermann M; Suchodolski JS; Steiner JM; Evans R
    J Vet Intern Med; 2010; 24(2):269-77. PubMed ID: 20051005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of disease severity and outcome of dietary, antibiotic, and immunosuppressive interventions by use of the canine IBD activity index in 21 dogs with chronic inflammatory bowel disease].
    Münster M; Hörauf A; Bilzer T
    Berl Munch Tierarztl Wochenschr; 2006; 119(11-12):493-505. PubMed ID: 17172138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A scoring index for disease activity in canine inflammatory bowel disease.
    Jergens AE; Schreiner CA; Frank DE; Niyo Y; Ahrens FE; Eckersall PD; Benson TJ; Evans R
    J Vet Intern Med; 2003; 17(3):291-7. PubMed ID: 12774968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Gawronska A; Banasiuk M; Lachowicz D; Pituch H; Albrecht P; Banaszkiewicz A
    Inflamm Bowel Dis; 2017 Dec; 23(12):2209-2214. PubMed ID: 29084080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.
    Segarra S; Martínez-Subiela S; Cerdà-Cuéllar M; Martínez-Puig D; Muñoz-Prieto A; Rodríguez-Franco F; Rodríguez-Bertos A; Allenspach K; Velasco A; Cerón J
    BMC Vet Res; 2016 Mar; 12():49. PubMed ID: 26965834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease.
    Rossi G; Pengo G; Caldin M; Palumbo Piccionello A; Steiner JM; Cohen ND; Jergens AE; Suchodolski JS
    PLoS One; 2014; 9(4):e94699. PubMed ID: 24722235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: Clinical and laboratory outcomes.
    Pérez-Merino EM; Usón-Casaús JM; Zaragoza-Bayle C; Duque-Carrasco J; Mariñas-Pardo L; Hermida-Prieto M; Barrera-Chacón R; Gualtieri M
    Vet J; 2015 Dec; 206(3):385-90. PubMed ID: 26526522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, controlled trial of budesonide and prednisone for the treatment of idiopathic inflammatory bowel disease in dogs.
    Dye TL; Diehl KJ; Wheeler SL; Westfall DS
    J Vet Intern Med; 2013; 27(6):1385-91. PubMed ID: 24112400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease.
    Otoni CC; Heilmann RM; García-Sancho M; Sainz A; Ackermann MR; Suchodolski JS; Steiner JM; Jergens AE
    J Vet Intern Med; 2018 May; 32(3):999-1008. PubMed ID: 29624721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease.
    Heilmann RM; Jergens AE; Ackermann MR; Barr JW; Suchodolski JS; Steiner JM
    Am J Vet Res; 2012 Dec; 73(12):1900-7. PubMed ID: 23176415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs.
    Chon SK; Kim NS
    Parasitol Res; 2005 Dec; 97(6):445-51. PubMed ID: 16151741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perinuclear antineutrophilic cytoplasmic antibody and response to treatment in diarrheic dogs with food responsive disease or inflammatory bowel disease.
    Luckschander N; Allenspach K; Hall J; Seibold F; Gröne A; Doherr MG; Gaschen F
    J Vet Intern Med; 2006; 20(2):221-7. PubMed ID: 16594575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of AST-120 in dogs with chronic idiopathic enteropathies.
    Volkmann M; Wirtherle NC; Beddies GF; Kohn B
    J Vet Intern Med; 2013; 27(6):1637-41. PubMed ID: 24128298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
    Isaacs KL; Sandler RS; Abreu M; Picco MF; Hanauer SB; Bickston SJ; Present D; Farraye FA; Wolf D; Sandborn WJ;
    Inflamm Bowel Dis; 2007 Oct; 13(10):1250-5. PubMed ID: 17567869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open-label trial.
    Dor C; Nixon S; Salavati Schmitz S; Bazelle J; Černá P; Kilpatrick S; Harvey ND; Dunning M
    J Small Anim Pract; 2024 May; 65(5):317-328. PubMed ID: 38354724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
    Prantera C; Lochs H; Grimaldi M; Danese S; Scribano ML; Gionchetti P;
    Gastroenterology; 2012 Mar; 142(3):473-481.e4. PubMed ID: 22155172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal S100A12 concentration predicts a lack of response to treatment in dogs affected with chronic enteropathy.
    Heilmann RM; Volkmann M; Otoni CC; Grützner N; Kohn B; Jergens AE; Steiner JM
    Vet J; 2016 Sep; 215():96-100. PubMed ID: 27017054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical signs, duodenal histopathological grades, and serum high-mobility group box 1 concentrations in dogs with inflammatory bowel disease.
    Lee JH; Kim HS; Lee D; Yun T; Koo Y; Chae Y; Kang JH; Kang BT; Yang MP; Kim H
    J Vet Intern Med; 2021 Sep; 35(5):2205-2214. PubMed ID: 34480505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, endoscopic and histopathological evaluation of the efficacy of budesonide in the treatment of inflammatory bowel disease in dogs.
    Rychlik A; Kołodziejska-Sawerska A; Nowicki M; Szweda M
    Pol J Vet Sci; 2016; 19(1):159-64. PubMed ID: 27096800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.